GlassScriptPhysician profile
Amanda Pechman
NPI 1942731567
$1,866.30
in general payments reported to CMS, 2019-2025
16 companies · $228 in 2025
The $228 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $370 · 2023: $982 · 2024: $287 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,496.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $646.54 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $205.02 | 2022-2024 | Mounjaro, Zepbound |
| Abbott Laboratories | $155.97 | 2024-2025 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $144.76 | 2023 | Tepezza |
| Dexcom, INC. | $138.66 | 2022-2023 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $126.54 | 2023 | Watchman Flx |
| Corcept Therapeutics | $104.49 | 2023 | Korlym |
| Abbvie INC. | $91.16 | 2023-2025 | |
| Currax Pharmaceuticals LLC | $84.99 | 2023-2025 | Contrave, Nexletol, Nexlizet |
| Sanofi-Aventis U.S. LLC | $51.45 | 2023 | |
| Intra-Sana Laboratories | $27.01 | 2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Bayer Healthcare Pharmaceuticals INC. | $24.19 | 2023 | |
| Tandem Diabetes Care, INC. | $19.44 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $16.97 | 2022 | |
| Radius Health, INC. | $14.98 | 2023 | Tymlos |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $14.13 | 2023 | Afrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Pechman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.